New Results
The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity
Emma C. Thomson, Laura E. Rosen, James G. Shepherd, Roberto Spreafico, Ana da Silva Filipe, Jason A. Wojcechowskyj, Chris Davis, Luca Piccoli, David J. Pascall, Josh Dillen, Spyros Lytras, Nadine Czudnochowski, Rajiv Shah, Marcel Meury, Natasha Jesudason, Anna De Marco, Kathy Li, Jessica Bassi, Aine O’Toole, Dora Pinto, Rachel M. Colquhoun, Katja Culap, Ben Jackson, Fabrizia Zatta, Andrew Rambaut, Stefano Jaconi, Vattipally B. Sreenu, Jay Nix, Ruth F. Jarrett, Martina Beltramello, Kyriaki Nomikou, Matteo Pizzuto, Lily Tong, Elisabetta Cameroni, Natasha Johnson, Arthur Wickenhagen, Alessandro Ceschi, Daniel Mair, Paolo Ferrari, Katherine Smollett, Federica Sallusto, Stephen Carmichael, Christian Garzoni, Jenna Nichols, Massimo Galli, Joseph Hughes, Agostino Riva, Antonia Ho, Malcolm G. Semple, Peter J.M. Openshaw, J. Kenneth Baillie, The ISARIC4C Investigators, the COVID-19 Genomics UK (COG-UK) consortium, Suzannah J. Rihn, Samantha J. Lycett, Herbert W. Virgin, Amalio Telenti, Davide Corti, David L. Robertson, Gyorgy Snell
doi: https://doi.org/10.1101/2020.11.04.355842
Emma C. Thomson
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
2Department of Clinical Research, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
Laura E. Rosen
3Vir Biotechnology, San Francisco, California 94158, USA
James G. Shepherd
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Roberto Spreafico
3Vir Biotechnology, San Francisco, California 94158, USA
Ana da Silva Filipe
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Jason A. Wojcechowskyj
3Vir Biotechnology, San Francisco, California 94158, USA
Chris Davis
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Luca Piccoli
4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
David J. Pascall
5Institute of Biodiversity, Animal Health and Comparative Medicine, Boyd Orr Centre for Population and Ecosystem Health, University of Glasgow, Glasgow, G61 1QH, UK
Josh Dillen
3Vir Biotechnology, San Francisco, California 94158, USA
Spyros Lytras
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Nadine Czudnochowski
3Vir Biotechnology, San Francisco, California 94158, USA
Rajiv Shah
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Marcel Meury
3Vir Biotechnology, San Francisco, California 94158, USA
Natasha Jesudason
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Anna De Marco
4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
Kathy Li
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Jessica Bassi
4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
Aine O’Toole
6Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK
Dora Pinto
4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
Rachel M. Colquhoun
6Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK
Katja Culap
4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
Ben Jackson
6Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK
Fabrizia Zatta
4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
Andrew Rambaut
6Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK
Stefano Jaconi
4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
Vattipally B. Sreenu
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Jay Nix
7Molecular Biology Consortium, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
Ruth F. Jarrett
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Martina Beltramello
4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
Kyriaki Nomikou
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Matteo Pizzuto
4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
Lily Tong
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Elisabetta Cameroni
4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
Natasha Johnson
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Arthur Wickenhagen
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Alessandro Ceschi
8Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland
9Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
10Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland
Daniel Mair
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Paolo Ferrari
11Department of Nephrology, Ospedale Civico Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland
12Prince of Wales Hospital Clinical School, University of New South Wales, Sydney, Australia
Katherine Smollett
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Federica Sallusto
13Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland
Stephen Carmichael
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Christian Garzoni
14Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland
Jenna Nichols
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Massimo Galli
15III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy
Joseph Hughes
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Agostino Riva
15III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy
Antonia Ho
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Malcolm G. Semple
16NIHR Health Protection Research Unit, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
17Respiratory Medicine, Alder Hey Children’s Hospital, Institute in The Park, University of Liverpool, Alder Hey Children’s Hospital, Liverpool L12 2AP, UK
Peter J.M. Openshaw
18National Heart and Lung Institute, Imperial College London, London, UK
J. Kenneth Baillie
19The Roslin Institute, University of Edinburgh, EH25 9RG Edinburgh, UK
20Intensive Care Unit, Royal Infirmary Edinburgh, Edinburgh, UK
Suzannah J. Rihn
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Samantha J. Lycett
19The Roslin Institute, University of Edinburgh, EH25 9RG Edinburgh, UK
Herbert W. Virgin
3Vir Biotechnology, San Francisco, California 94158, USA
23Washington University School of Medicine, Saint Louis, Missouri 63110, USA
Amalio Telenti
3Vir Biotechnology, San Francisco, California 94158, USA
Davide Corti
4Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
David L. Robertson
1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
Gyorgy Snell
3Vir Biotechnology, San Francisco, California 94158, USA
Article usage
Posted November 05, 2020.
The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity
Emma C. Thomson, Laura E. Rosen, James G. Shepherd, Roberto Spreafico, Ana da Silva Filipe, Jason A. Wojcechowskyj, Chris Davis, Luca Piccoli, David J. Pascall, Josh Dillen, Spyros Lytras, Nadine Czudnochowski, Rajiv Shah, Marcel Meury, Natasha Jesudason, Anna De Marco, Kathy Li, Jessica Bassi, Aine O’Toole, Dora Pinto, Rachel M. Colquhoun, Katja Culap, Ben Jackson, Fabrizia Zatta, Andrew Rambaut, Stefano Jaconi, Vattipally B. Sreenu, Jay Nix, Ruth F. Jarrett, Martina Beltramello, Kyriaki Nomikou, Matteo Pizzuto, Lily Tong, Elisabetta Cameroni, Natasha Johnson, Arthur Wickenhagen, Alessandro Ceschi, Daniel Mair, Paolo Ferrari, Katherine Smollett, Federica Sallusto, Stephen Carmichael, Christian Garzoni, Jenna Nichols, Massimo Galli, Joseph Hughes, Agostino Riva, Antonia Ho, Malcolm G. Semple, Peter J.M. Openshaw, J. Kenneth Baillie, The ISARIC4C Investigators, the COVID-19 Genomics UK (COG-UK) consortium, Suzannah J. Rihn, Samantha J. Lycett, Herbert W. Virgin, Amalio Telenti, Davide Corti, David L. Robertson, Gyorgy Snell
bioRxiv 2020.11.04.355842; doi: https://doi.org/10.1101/2020.11.04.355842
The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity
Emma C. Thomson, Laura E. Rosen, James G. Shepherd, Roberto Spreafico, Ana da Silva Filipe, Jason A. Wojcechowskyj, Chris Davis, Luca Piccoli, David J. Pascall, Josh Dillen, Spyros Lytras, Nadine Czudnochowski, Rajiv Shah, Marcel Meury, Natasha Jesudason, Anna De Marco, Kathy Li, Jessica Bassi, Aine O’Toole, Dora Pinto, Rachel M. Colquhoun, Katja Culap, Ben Jackson, Fabrizia Zatta, Andrew Rambaut, Stefano Jaconi, Vattipally B. Sreenu, Jay Nix, Ruth F. Jarrett, Martina Beltramello, Kyriaki Nomikou, Matteo Pizzuto, Lily Tong, Elisabetta Cameroni, Natasha Johnson, Arthur Wickenhagen, Alessandro Ceschi, Daniel Mair, Paolo Ferrari, Katherine Smollett, Federica Sallusto, Stephen Carmichael, Christian Garzoni, Jenna Nichols, Massimo Galli, Joseph Hughes, Agostino Riva, Antonia Ho, Malcolm G. Semple, Peter J.M. Openshaw, J. Kenneth Baillie, The ISARIC4C Investigators, the COVID-19 Genomics UK (COG-UK) consortium, Suzannah J. Rihn, Samantha J. Lycett, Herbert W. Virgin, Amalio Telenti, Davide Corti, David L. Robertson, Gyorgy Snell
bioRxiv 2020.11.04.355842; doi: https://doi.org/10.1101/2020.11.04.355842
Subject Area
Subject Areas
- Biochemistry (11744)
- Bioengineering (8751)
- Bioinformatics (29193)
- Biophysics (14968)
- Cancer Biology (12094)
- Cell Biology (17411)
- Clinical Trials (138)
- Developmental Biology (9421)
- Ecology (14178)
- Epidemiology (2067)
- Evolutionary Biology (18303)
- Genetics (12244)
- Genomics (16801)
- Immunology (11866)
- Microbiology (28082)
- Molecular Biology (11592)
- Neuroscience (60959)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4957)
- Plant Biology (10427)
- Synthetic Biology (2885)
- Systems Biology (7339)
- Zoology (1651)